Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




New Drugs May Block Muscular Dystrophy's Toxic RNA

By LabMedica International staff writers
Posted on 01 Dec 2008
A research team seeking drugs to treat muscular dystrophy have used techniques from the realm of dynamic combinatorial chemistry to identify several promising compounds.

Dynamic combinatorial chemistry integrates synthesis of chemical libraries and screening in one process, potentially accelerating the discovery of useful compounds. In the dynamic approach, the libraries are not created as arrays of individual compounds, but are generated as mixtures of components, similar to natural pools of antibodies. One important requirement is that the mixture components exist in dynamic equilibrium with each other. According to basic laws of thermodynamics, if one of the components is removed from the equilibrated mixture--by binding to the target molecule, for example--the system will respond by producing more of the removed component to maintain the equilibrium balance in the mixture.

The dynamic mixture, as any other combinatorial library, is so designed that some of the components have potentially high affinity to a bio-molecular target. These high-affinity components can form strong complexes with the target. If the target is added to the equilibrated mixture, when the effective components form complexes with the target they are removed from the equilibrium. This forces the system to make more of these components at the expense of other ones that bind to the target with less strength. As a result of such an equilibrium shift, the combinatorial library reorganizes to increase the amount of strong binders and decrease the amount of the weaker ones. This reorganization leads to enrichment of the library with the effective components and simplifies their identification.

In the current study, investigators at the University of Rochester Medical Center (New York, NY, USA) used dynamic combinatorial chemistry to seek compounds that would prevent the binding of muscular dystrophy's characteristic toxic RNA – with hundreds or even thousands of CUG base repeats – to the splicing regulator protein MBNL1.

They reported in the November 8, 2008, online edition of the Journal of the American Chemical Society that the method allowed the simultaneous testing of 11,000 compounds and yielded several molecules with significant selectivity for binding to CUG repeat RNA.

"The drug discovery field really is wide open when it comes to RNA, which is a very difficult molecule to target,” said senior author Dr. Benjamin Miller, associate professor of biochemistry and biophysics at the University of Rochester Medical Center. "This discovery gives us, for the first time, a molecule that targets the wayward RNA at the root of myotonic muscular dystrophy. This is a first step toward developing a drug-like molecule that perhaps could be used someday to treat the disease. This lead molecule provides a framework for moving forward.”

Related Links:
University of Rochester Medical Center


Gold Member
Veterinary Hematology Analyzer
Exigo H400
Verification Panels for Assay Development & QC
Seroconversion Panels
New
HIV Test
Anti-HIV (1/2) Rapid Test Kit
New
Biological Indicator Vials
BI-O.K.
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: The tiny clay-based materials can be customized for a range of medical applications (Photo courtesy of Angira Roy and Sam O’Keefe)

‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection

Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Pathology

view channel
Image: The ready-to-use DUB enzyme assay kits accelerate routine DUB activity assays without compromising data quality (Photo courtesy of Adobe Stock)

Sensitive and Specific DUB Enzyme Assay Kits Require Minimal Setup Without Substrate Preparation

Ubiquitination and deubiquitination are two important physiological processes in the ubiquitin-proteasome system, responsible for protein degradation in cells. Deubiquitinating (DUB) enzymes contain around... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.